Limited comparison of baseline characteristics due to lack of age stratification in many studies. Higher risk of bleeding events with prasugrel/ticagrelor vs clopidogrel. No difference in efficacy endpoint rates. Results unchanged after excluding non-RCTs, high statistical heterogeneity in endpoint analysis.